Cambridge based Congenica, who developed the gold standard genome analytics platform Sapientia, have now opened offices and created new partnerships across three continents; Asia, Europe and the Americas.

Congenica, which was only established in 2014, saw its series B funding completed in April of this year with investment from Chinese genomics giant the Beijing Genomics Institute (BGI) who are the one of the world’s largest DNA sequencing providers.

“Genetic analytics software will be a central part of China’s evolving healthcare system in the coming years. We are delighted to be at the forefront of this change and committed to the benefits it will bring to patients.” Said Congenica’s Chief Business Officer, Shikha O’Brien.

Another of Congenica’s partnerships is in supporting China’s 100K Wellness Pioneer Project, designed to gather 100,000 full genomes from Chinese individuals, both as a healthcare tool, and to aid in diversifying global genomic knowledge, which has previously been focused on genomes that are of European origin or descent.

The Chinese investors and partners have also signed up to use Congenica’s proprietary enterprise software Sapientia, which was used extensively by Genomics England on the 100K genomes project, meaning Congenica are in a position of rarefied experience to aid in this task.

“The unrivalled, integrated, end to end solution provided by the Sapientia software offers multiple advantages.” Said, Li Ning, Chief Development Officer at BGI.

Congenica have also seen new offices opening in California and Delaware in the U.S. where the company is enjoying increasing success and market penetration.

Closer to home the company have struck a deal with Portugal’s Coimbra Paediatric Hospital (CPH) where Sapientia will perform whole exome sequencing for the In2Genome project, which aims to revolutionize the diagnosis of rare genetic diseases through population wide genomic data.

“This additional investment, these new contracts and our new locations are all part of our international ambitions and they enhance our ability to deploy Sapientia to markets where we are establishing scalable partnership models to transform genetic testing.” Said Tom Weaver, CEO of Congenica.